BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer

Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., Wolff G.

Source: Eur Respir J 2002; 19: 134-140
Journal Issue: January
Disease area: Thoracic oncology

Congress or journal article abstractPDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Gessner C., Liebers U., Kuhn H., Stiehl P., Witt C., Schauer J., Wolff G.. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002; 19: 134-140

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001

Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer
Source: Eur Respir J 2001; 17: 660-666
Year: 2001



The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003

The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Source: Eur Respir J 2009; 33: 127-133
Year: 2009



Correlation between expression of p53, pRb, mdm2, p21WAF1/CIP1, PCNA, cyclin D1 and apoptotic index (AI) in non-small cell lung cancer (NSCLC) cells
Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer
Year: 2006


The role of HER-2/neu, p53, Bcl-2 and Ki-67 in patients with lung cancer
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019

Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer
Source: Eur Respir J 2004; 23: 14-19
Year: 2004



Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002

Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010

Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer
Source: Eur Respir J 2013; 41: 1172-1178
Year: 2013



The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 478s
Year: 2001

Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis
Source: Eur Respir J 2002; 20: 703-709
Year: 2002



Expression of p53, Bcl-2 and Bax in non-small cell lung cancer
Source: Eur Respir J 2007; 30: Suppl. 51, 512s
Year: 2007

The positive prognostic impact of Bcl-xl and Bcl-2 in chemo-naive lung cancer patients depends on stage and histology
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Prognostic value of p21 protein expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Source: Eur Respir J 2012; 40: 177-184
Year: 2012



Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 136-142
Year: 2011



MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002

TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005